Bill Summary for H 1101 (2021-2022)
|View NCGA Bill Details||2021|
AN ACT ESTABLISHING A PILOT PROGRAM TO ASSESS THE EFFECTIVENESS OF PRESCRIPTION DIGITAL THERAPEUTICS AUTHORIZED BY THE FEDERAL FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF OPIOID USE DISORDER; AND APPROPRIATING FUNDS FOR THAT PURPOSE.Intro. by K. Baker, Warren, Blackwell, Miller.
|View: All Summaries for Bill||Tracking:|
Sets out legislative intent. Requires the State Controller to transfer $1,850,000 for 2022-23 from funds in the Opioid Abatement Reserve to the Opioid Abatement Fund and appropriates those funds to the Department of Health and Human Services, Division of Mental Health, Developmental Disabilities, and Substance Abuse Services (Division) to develop and administer a two-year pilot program to gauge the effectiveness of prescription digital therapeutics (PDTs) authorized by the FDA to treat opioid use disorder. Specifies that the funds remain available to expend until the sooner of December 1, 2024, or the termination of the program.
Requires the program to commence by December 1, 2022, and terminate by December 1, 2024. Requires the Division to determine the number of sites at which the program will be conducted; eligibility requirements for participants; and the types of PDTs that will be prescribed and evaluated. Allows the Division to use up to $150,000 of these funds for administrative purposes.
Requires the Division to submit a report within six months of terminating the program to the specified NCGA committee on the program's impacts, including ten specified items.
Effective July 1, 2022.